Navegar por autor "Antolín Novoa, Silvia"

A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study

2011- Antolín Novoa, Silvia; García Mata, Jesús; Álvarez Gómez, Elena; Mel Lorenzo, José Ramón; De Paz Arias , Laura [et al.]

Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice

2015- Antolín Novoa, Silvia

ADJUVANT TREATMENT USED WITH TRASTUZUMAB IN BREAST CANCER WITH <= 1.5 cm TUMOR SIZE PATIENTS

2013- Antolín Novoa, Silvia

Analysis of metastatic breast cancer management across Europe - The EOS study (European Observatory & Survey)

2011- Antolín Novoa, Silvia

BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

2019- Barnadas, A.; Munoz, M.; Margeli, M.; Chacon, J. I.; Cassinello, J.; [et al.]

Circulating miR-200c and miR-141 and outcomes in patients with breast cancer

2015- Valladares Ayerbes, Manuel; Haz Conde, María del Mar; Blanco Calvo, Moisés; Antolín Novoa, Silvia; Antón Aparicio, Luis Miguel; [et al.]

ConvertHER: Evolution of genomic alterations from primary to metastatic breast cancer

2015- Antolín Novoa, Silvia

Dolor como factor predictor de depresion en el paciente oncologico: estudio de casos y controles. Estudio D-PRESS.

2013- Antolín Novoa, Silvia; Jorge Fernández, Monica; García. Gómez, Jesús

Evaluación de un programa de reconstrucción mamaria inmediata mediante expansión-prótesis en mujeres con cáncer de mama

2014- Acea Nebril, Benigno; Antolín Novoa, Silvia; Mosquera Oses, Joaquín José; Cereijo Garea, Carmen; Calvo Martínez, Lourdes; [et al.]

Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study

2014- Antolín Novoa, Silvia

Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: Final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial

2012- Antolín Novoa, Silvia

Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention

2017-09- Cueva Bañuelos, Juan Fernando; Antolín Novoa, Silvia; Calvo Martínez, Lourdes; Fernández, I; Ramos, M; [et al.]

Guía gallega de manejo de la trombosis asociada a cáncer

2019-10-25- Campos Balea, Begoña; Fernández Bouza, Elena; Barbagelata López, Cristina; Brozos Vázquez, Elena María; CAROU FRIEIRO, IRIA; [et al.]

Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study

2015- Antolín Novoa, Silvia

Lurbinectedin (PM01183) activity in BRCA1/2-associated or unselected metastatic breast cancer. Interim results of an ongoing phase II trial

2015- Antolín Novoa, Silvia

Micrornas as emerging biomarkers for micrometastasis detection in breast tumors

2012- Valladares Ayerbes, Manuel; Haz Conde, María del Mar; Blanco Calvo, Moisés; Antolín Novoa, Silvia; Antón Aparicio, Luis Miguel; [et al.]

MicroRNAs as emerging biomarkers for micrometastasis detection in genitourinary tumors

2011- Valladares Ayerbes, Manuel; Antolín Novoa, Silvia; Antón Aparicio, Luis Miguel; Reboredo Lopez, Margarita; Aparicio Gallego, Guadalupe; [et al.]

Nabrax: nab-paclitaxel as neoadjuvant therapy of breast cancer: interim safety of geicam 2011-02

2013- Antolín Novoa, Silvia

NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer

2019- S.A., Jacobs; A., Robidoux; J., Abraham; J.M., Perez-Garcia; N., La Verde; [et al.]

Phase I study of dasatinib in combination with trastuzumab and paclitaxel in patients with HER2 positive metastatic breast cancer

2014- Antolín Novoa, Silvia

Repositorio digital RUNA

Navegar por autor "Antolín Novoa, Silvia"

A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study ﻿

Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice ﻿

ADJUVANT TREATMENT USED WITH TRASTUZUMAB IN BREAST CANCER WITH <= 1.5 cm TUMOR SIZE PATIENTS ﻿

Analysis of metastatic breast cancer management across Europe - The EOS study (European Observatory & Survey) ﻿

BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study ﻿

Circulating miR-200c and miR-141 and outcomes in patients with breast cancer ﻿

ConvertHER: Evolution of genomic alterations from primary to metastatic breast cancer ﻿

Dolor como factor predictor de depresion en el paciente oncologico: estudio de casos y controles. Estudio D-PRESS. ﻿

Evaluación de un programa de reconstrucción mamaria inmediata mediante expansión-prótesis en mujeres con cáncer de mama ﻿

Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study ﻿

Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: Final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial ﻿

Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention ﻿

Guía gallega de manejo de la trombosis asociada a cáncer ﻿

Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study ﻿

Lurbinectedin (PM01183) activity in BRCA1/2-associated or unselected metastatic breast cancer. Interim results of an ongoing phase II trial ﻿

Micrornas as emerging biomarkers for micrometastasis detection in breast tumors ﻿

MicroRNAs as emerging biomarkers for micrometastasis detection in genitourinary tumors ﻿

Nabrax: nab-paclitaxel as neoadjuvant therapy of breast cancer: interim safety of geicam 2011-02 ﻿

NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer ﻿

Phase I study of dasatinib in combination with trastuzumab and paclitaxel in patients with HER2 positive metastatic breast cancer ﻿

A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study

Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice

ADJUVANT TREATMENT USED WITH TRASTUZUMAB IN BREAST CANCER WITH <= 1.5 cm TUMOR SIZE PATIENTS

Analysis of metastatic breast cancer management across Europe - The EOS study (European Observatory & Survey)

BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

Circulating miR-200c and miR-141 and outcomes in patients with breast cancer

ConvertHER: Evolution of genomic alterations from primary to metastatic breast cancer

Dolor como factor predictor de depresion en el paciente oncologico: estudio de casos y controles. Estudio D-PRESS.

Evaluación de un programa de reconstrucción mamaria inmediata mediante expansión-prótesis en mujeres con cáncer de mama

Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study

Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: Final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial

Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention

Guía gallega de manejo de la trombosis asociada a cáncer

Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study

Lurbinectedin (PM01183) activity in BRCA1/2-associated or unselected metastatic breast cancer. Interim results of an ongoing phase II trial

Micrornas as emerging biomarkers for micrometastasis detection in breast tumors

MicroRNAs as emerging biomarkers for micrometastasis detection in genitourinary tumors

Nabrax: nab-paclitaxel as neoadjuvant therapy of breast cancer: interim safety of geicam 2011-02

NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer

Phase I study of dasatinib in combination with trastuzumab and paclitaxel in patients with HER2 positive metastatic breast cancer